2015
DOI: 10.1016/j.jval.2015.08.008
|View full text |Cite
|
Sign up to set email alerts
|

Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women

Abstract: Anthracycline-based chemotherapy was found cost-effective for elderly patients with early stage (stage I, II, IIIa) breast cancer considering the US threshold of $100,000 per QALY. Further research may be needed to characterize differential effects across age groups.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(2 citation statements)
references
References 58 publications
0
2
0
Order By: Relevance
“…A total of 7 articles estimated the cost effectiveness of chemotherapy (n = 2), hormone receptor-targeted therapy (n = 1), and human epidermal growth factor receptor 2 (HER2)-targeted therapy (n = 4) in the neoadjuvant and adjuvant settings. [47][48][49][50][51][52][53] Adjuvant treatment with anthracyclines 47 had favorable incremental cost-effectiveness ratios (ICERs) compared with non-anthracycline-based chemotherapy regimens (dominated) or no chemotherapy ($7,688 per QALY) considering a WTP threshold of $100,000 per QALY among elderly women diagnosed with hormone receptor-positive, stage I, II, or IIIA breast cancer. Among women with hormone receptor-positive tumors, extended tamoxifen was more cost effective compared with ovarian ablation plus aromatase inhibitors (dominated) or no further treatment ($4,042 per life-year).…”
Section: Systemic Treatmentmentioning
confidence: 99%
“…A total of 7 articles estimated the cost effectiveness of chemotherapy (n = 2), hormone receptor-targeted therapy (n = 1), and human epidermal growth factor receptor 2 (HER2)-targeted therapy (n = 4) in the neoadjuvant and adjuvant settings. [47][48][49][50][51][52][53] Adjuvant treatment with anthracyclines 47 had favorable incremental cost-effectiveness ratios (ICERs) compared with non-anthracycline-based chemotherapy regimens (dominated) or no chemotherapy ($7,688 per QALY) considering a WTP threshold of $100,000 per QALY among elderly women diagnosed with hormone receptor-positive, stage I, II, or IIIA breast cancer. Among women with hormone receptor-positive tumors, extended tamoxifen was more cost effective compared with ovarian ablation plus aromatase inhibitors (dominated) or no further treatment ($4,042 per life-year).…”
Section: Systemic Treatmentmentioning
confidence: 99%
“…,Hassett et al (2014),Hastert et al (2014),Hernandez et al (2015),Hershman et al (2006),Hill et al (2010),Holmes et al (2010),Hossain et al (2008),Hu et al (2013),Iqbal et al (2015),Jatoi et al (2005),Javid et al (2014),Joslyn (2002),Kaplan et al (2015),Keegan et al (2015),Kirsner et al (2006),Kish et al (2014),Lairson et al (2015),,Liu et al (2013),Maggard et al (2003), Hines (2012), McCarthy et al (2007),Menashe et al (2009),Meng et al (1997a),Meng et al (1997b),Miller et al (2008), Mueller et al (2015), Ning et al (2015), Nurgalieva et al (2013c), Nurgalieva et al (2013a), Nurgalieva et al (2013b), O'Malley et al (2003), Onega et al (2010), Ooi and Martinez (2011), Ortiz et al (2010), Pellatt et al (2016), Polednak (2002), Roetzheim et al (2008), Schlichting et al (2012), Schonberg et al (2010), Schootman et al (2008), Shavers et al (2003), Silber et al (2013), Simon and Severson (1997), Simon and Severson (2006), Smith-Gagen et al (2013), Swede et al (2011), Wagner et al (2012), Robin (2003), Yi et al (2012), Schinkel et al (2014), Trinh et al (2015), Zeng et al (2015) 87 33.9 Census Adams et al (2015), Albano et al (2007), Akinyemiju et al (2013b), Cheng et al (2015), Chien et al (2015), Chu et al (2007), Haji-Jama et al (2016), Hastert et al (2014), Hu et al (2013), Hunt et al (2014), Keegan et al (2015), Kish et al (2014), Markossian et al (2012), McCarthy et al (2015), Mueller et al (2015), Okunade and Karakus (2003), Parise and Caggiano (2015), Pezzin et al (2015), Philips Jr et al (2013), Pruitt et al (2015), Rajan et al (2015), Roseland et al (2015), Russell et al (2011), Rust et al (2015), Shariff-Marco et al (2015b), Shariff-Marco et al (2015a), Schlichting et al (2012), Schootman et al (2008), Simon and Severson (1997), Singh et al (2011), Sprague et al (2011), Steenland et al (2004), Tannenbaum et al (2013), Tao et al (2015), Tian et al (2011), Trinh et al (2015), Vinnakota and Lam (2006), Wagner et al (2012), Whitman et al (2012), Robin (2003) 42 15.4 Collection of DNA, interview, chart, or observational data Boone et al (2014b), Boone et al (2014a), Boone et al (2015), Connor et al (2013), Connor et al (2014), Connor et al (2016b), Connor et al (2016a), Cheng et al (2015), Gordon et al (1992), George et al (2013), Haster...…”
mentioning
confidence: 99%